长江商报消息 ●长江商报记者 沈右荣 追求资产价值最大化，上海医药（601607.SH）拟出售资产。 2月4日晚，上海医药公告，公司拟通过公开挂牌方式转让中美上海施贵宝制药有限公司（简称"中美施 贵宝"）30%股权，转让价格不低于10.23亿元。 2025年，中美施贵宝60%股权对外出售，潜在收购方提交的中美施贵宝100%股权的报价为4.8亿美元。 上海医药公告称，在市场化报价下实现股权退出更能够实现资产价值最大化，遂寻求转让所持标的公司 股权。 上海医药主营业务覆盖医药工业和医药商业。近年来，公司加速创新转型，通过打造具有优势的药物研 发、临床研究、中试生产、产业化制造及营销推广的工业体系，提升综合竞争力。 2021年至2024年，上海医药研发投入合计超过百亿元，2025年前三季度，研发投入逾15亿元。 上海医药取得了不菲的研发成果。2025年12月，公司自研新药SPH3127片高血压适应症已正式获批上 市，一种渐冻症新药已启动III期临床试验。 上海医药盈利能力较强。2025年前三季度，公司实现的归母净利润超过50亿元。 超10亿转让或获利7.67亿 上海医药选择出手，退出中美施贵宝股东之列。 1982年 ...

Core Viewpoint - Changchun High-tech (000661.SZ) is expected to experience a significant decline in operating performance, with a projected net profit attributable to shareholders of 150 million to 220 million yuan for 2025, representing a year-on-year decrease of over 90% [1][4]. Group 1: Financial Performance - In 2024, Changchun High-tech's net profit attributable to shareholders decreased by over 40% year-on-year [2]. - For 2025, the company anticipates a net profit drop of 24.33 billion to 23.63 billion yuan compared to the previous year, with a decline rate of 91.48% to 94.19% [4]. - The company reported a net profit of 1.165 billion yuan for the first three quarters of 2025, down 58.23% year-on-year, with total revenue of 9.807 billion yuan, a decrease of 5.60% [4]. Group 2: Factors Influencing Performance - The decline in net profit is attributed to adjustments in pricing and sales policies for core products, particularly long-acting growth hormones, due to their inclusion in the national medical insurance directory [2][6]. - Increased research and development (R&D) expenses, which reached 2.690 billion yuan in 2024, and higher sales expenses have also impacted profitability [10][12]. - The company is focusing on R&D in traditional areas such as endocrine metabolism and women's health, as well as innovative directions related to tumors, respiratory, and immune systems [10]. Group 3: R&D and Product Development - Changchun High-tech's R&D investment for the first three quarters of 2025 was 1.733 billion yuan, a year-on-year increase of 22.91% [12]. - The company has successfully advanced several products, including the GenSci098 injection project, which received a 70 million USD upfront payment [3][14]. - The R&D expenses have been steadily increasing, with a total of 2.690 billion yuan in 2024, representing 19.97% of total revenue [10]. Group 4: Market Position and Future Outlook - The company has historically relied heavily on growth hormones, which have been referred to as its "cash cow" [6]. - The future ability of Changchun High-tech to reduce its dependence on growth hormones is a key concern for investors [15].

Core Viewpoint - The national drug supervision work conference held in Beijing emphasizes the support for the development and efficiency enhancement of the pharmaceutical industry, alongside the implementation of comprehensive drug regulatory reforms [1] Group 1: Industry Development - The conference aims to support pharmaceutical research and innovation, promote the development of traditional Chinese medicine, and encourage high-level self-reliance in medical devices [1] - Analyst Hou Yanan from Bohai Securities predicts that by 2025, the total amount of innovative drug licensing transactions in China will exceed $130 billion, with over 150 transactions, setting a historical record [1] - China's pipeline of new drugs under research accounts for approximately 30% of the global total, ranking second worldwide, indicating a sustained trend in the innovative drug industry [1] Group 2: Investment Opportunities - The upcoming JPM Healthcare Conference scheduled for January 12-15, 2026, in San Francisco is highlighted, suggesting a focus on the strategic developments of related companies [1] - There are investment opportunities in the innovative drug sector, CXO, and upstream life sciences industries, as indicated by the ongoing trends in the pharmaceutical market [1]

Meeting Overview - The 34th meeting of the 9th Board of Directors of China Pharmaceutical Health Industry Co., Ltd. was held on December 29, 2025, combining in-person and communication methods, chaired by Chairman and General Manager Yang Guang [2] - All 8 directors attended the meeting, and the meeting complied with the relevant provisions of the Company Law and the Articles of Association, making the resolutions valid [4][5] Resolutions Passed - The board approved the proposal to acquire 70% equity of Shanghai Zezheng Pharmaceutical Technology Co., Ltd. for a cash consideration of 525 million RMB [6][14] - The board also approved the revision of the "System Management Measures" [8][9] Transaction Details - The acquisition aims to enhance the company's comprehensive strength in pharmaceutical research and development, addressing current shortcomings in its R&D system and achieving a full industry chain from research to production [18] - The total transaction amount is 525 million RMB, funded by the company's own and/or self-raised funds [18] - After the transaction, the company will hold 70% of Zezheng Pharmaceutical, which will become a subsidiary included in the company's consolidated financial statements [18] Financial Overview of the Target Company - As of September 30, 2025, Zezheng Pharmaceutical had total assets of 421.63 million RMB and net assets of 264.62 million RMB, with a revenue of 107.29 million RMB and a net loss of 40.85 million RMB for the first nine months of 2025 [47] - The valuation of Zezheng Pharmaceutical was assessed at 758.84 million RMB using the income approach, indicating a significant increase in value [48] Strategic Importance of the Transaction - The acquisition is expected to strengthen the company's position in the pharmaceutical R&D sector, allowing for deeper integration of technology, market, and resources, and enhancing competitiveness [63] - The management of Zezheng Pharmaceutical will be arranged according to the agreement, ensuring the company's legal rights and control [63]

Core Viewpoint - China Medical (600056.SH) aims to enhance its comprehensive strength in pharmaceutical R&D innovation by acquiring a 70% stake in Shanghai Zezheng Pharmaceutical Technology Co., Ltd. for RMB 525 million, thereby addressing current R&D system shortcomings and integrating the entire industry chain from R&D to production [1] Group 1 - The acquisition will be funded through the company's own and/or self-raised funds [1] - After the transaction, Zezheng Pharmaceutical will become a wholly-owned subsidiary of China Medical, included in the consolidated financial statements [1] - This move is expected to strengthen the company's capabilities in pharmaceutical R&D, facilitating deep integration in technology, market, and resources [1] Group 2 - The transaction aims to enhance the company's layout in various fields, including generic drug research, improved new drug research, and innovative drug research [1] - The integration is intended to create a collaborative development framework among pharmaceutical R&D, industrial production, and commercial operations [1] - This strategic acquisition is anticipated to further improve the competitiveness of the listed company in the pharmaceutical industry [1]

Core Viewpoint - The company has signed a share purchase agreement to acquire 70% of Shanghai Zezheng Pharmaceutical Technology Co., Ltd. for a cash investment of 525 million RMB, aiming to enhance its capabilities in pharmaceutical R&D innovation and address current shortcomings in its R&D system [1] Group 1: Transaction Details - The total cash investment for the acquisition is 525 million RMB [1] - The transaction involves 13 counterparties who collectively hold the shares being purchased [1] - The acquisition will result in Shanghai Zezheng becoming a wholly-owned subsidiary of the company [1] Group 2: Strategic Objectives - The primary goal of the transaction is to strengthen the company's overall strength in the pharmaceutical R&D innovation sector [1] - The acquisition is intended to bridge the gap in the current R&D system and facilitate a full industry chain from research and development to production [1] - The transaction has been approved by the board of directors and does not require shareholder approval [1]

Core Viewpoint - The National Medical Products Administration (NMPA) emphasizes the importance of enhancing drug regulation in 2024, focusing on creating a transparent and predictable regulatory environment to support pharmaceutical innovation and contribute to national economic development [1] Group 1: Drug Safety and Regulation - The NMPA aims to improve drug safety assurance levels and establish a robust drug safety responsibility system, including a regular risk consultation mechanism to address risks at an early stage [1] - There is a commitment to strengthen the regulation of key drugs, especially in light of the increased incidence of respiratory diseases during winter [1] Group 2: Support for Pharmaceutical Industry - The NMPA plans to enhance the quality and efficiency of drug review and approval processes, implementing tailored strategies for key products and supporting the development of innovative drugs and medical devices [1] - The agency will promote the coordinated development of the "three medical" sectors (medical insurance, medical care, and pharmaceuticals) and ensure the quality and efficacy consistency of generic drugs according to international standards [1] Group 3: Regulatory System and Capacity Building - There is a focus on strengthening the regulatory system and capacity, improving the legal and standard framework, and advancing smart regulation and regulatory science to modernize drug regulation [1] - The NMPA is tasked with planning key work for the upcoming year to ensure the successful completion of the 14th Five-Year Plan and a strong start to the 15th Five-Year Plan [1]

Core Viewpoint - Company reported stable revenue and robust profit growth in the first half of 2025, with a focus on strengthening its position in the biopharmaceutical sector and expanding its product matrix through innovation [1][2]. Financial Performance - In the first half of 2025, the company achieved revenue of 1.239 billion yuan, essentially flat year-on-year; however, net profit attributable to shareholders increased by 6.65% to 38.81 million yuan, and net profit excluding non-recurring items rose by 36.34% to 36.85 million yuan [1]. Product Development and Sales - The strategic product, "Hydromorphone Hydrochloride Injection," saw revenue growth exceeding 90% year-on-year, becoming a key pillar for the company [2]. - The company is expanding its product line with ongoing research and development, including applications for sustained-release hydromorphone tablets and acetaminophen-hydromorphone tablets, which are currently under review [2][3]. - The company is also focusing on both formulation sales and raw material production, establishing partnerships with other pharmaceutical companies to enhance its competitive edge in the hydromorphone market [3]. Market Position and Strategy - The company has solidified its market position in traditional therapeutic areas such as cardiovascular diseases, with core products like "Benidipine Hydrochloride Tablets" capturing 55% of the market share in its category [4]. - The company has successfully expanded its market presence in non-collection markets, achieving over 20% growth in recent years for its core products [4]. - The company has also made significant strides in the OTC channel, with products like "Huasu Tablets" and "Naloxone Sublingual Tablets" receiving recognition at health conferences [5]. Regulatory Environment and Future Outlook - Recent changes in national procurement policies may benefit the company by allowing for brand-based volume reporting, which could enhance its market share in key therapeutic areas [6]. - The company is actively developing a comprehensive pain management product matrix, including new drugs and raw materials, which is expected to bolster its market position [7]. - The company has attracted attention from various investment institutions, indicating strong market recognition and potential for future growth [8].

Core Viewpoint - Longshen Rongfa (300534.SZ) reported a steady growth in revenue and net profit for the first half of 2025, demonstrating resilience in a challenging economic environment and a competitive pharmaceutical industry [1] Financial Performance - The company achieved an operating income of 496 million yuan and a net profit attributable to shareholders of 27.96 million yuan, representing a year-on-year increase of 27.48% [1] - The net profit after deducting non-recurring gains and losses reached 30.49 million yuan, up 39.93% compared to the previous year [1] Product and Market Development - Longshen Rongfa focuses on its core pharmaceutical business, enhancing its marketing system and brand building, which has led to increased hospital coverage for its key products [1] - The core products, Yuanhu Zhitong Diban and Xuanfei Zhiso Heji, covered 2,858 and 2,299 hospitals respectively, with coverage rates increasing to 19.39% and 15.56% [1] - Revenue from the drop pill products grew by 31.22% year-on-year, indicating effective market promotion [1] Product Recognition - Yuanhu Zhitong Diban and Xuanfei Zhiso Heji received multiple industry awards for their clinical efficacy and brand recognition [2] - Xuanfei Zhiso Heji ranked 7th in the "2024 China Innovative Drug Sales Enterprise Ranking (Traditional Chinese Medicine) TOP20" [2] - Yuanhu Zhitong Diban was listed among the top 20 brands in sales for traditional Chinese medicine pills in public medical institutions [2] Project Development - The company made significant progress in capacity enhancement and technology upgrades, including the acquisition of 70% of the Innovative Research Institute [3] - The production line upgrade for Xuanfei Zhiso Heji has been completed and passed GMP compliance checks, ready for production [3] - The construction and registration of a new production line for blood dialysis concentrate is underway, expected to become a new growth point [3] R&D Innovation - Longshen Rongfa established a technical center laboratory with Puan Pharmaceutical to facilitate the industrialization of R&D results [4] - Ongoing research includes real-world studies for Xuanfei Zhiso Heji and new formulations for Yuanhu Zhitong Diban [4] - The company collaborates with Lanzhou University for health food R&D, with several products launched through dual-channel marketing [4] Investor Returns and Social Responsibility - The company plans to distribute a cash dividend of 0.2 yuan per 10 shares to all shareholders for the first half of 2025 [4] - Longshen Rongfa has been recognized as a "green factory" and included in the list of high-tech, high-growth enterprises in Gansu Province [4]

Group 1 - The core viewpoint of the report is that Dongguan Securities has given a "buy" rating to Fuyuan Pharmaceutical (601089.SH) with a latest price of 30.8 yuan [2] - The reasons for the rating include a slowdown in the company's Q2 performance growth and an acceleration in the promotion of research and development innovation [2]